Il23r ва il17f генлари полиморфизмларининг вульгар псориаз кечиши оғирлиги билан боғлиқлиги ва прогностик аҳамияти
Kalit so‘zlar:
вульгар псориазAbstrak
IL23R (rs11209026) ва IL17F (C/G, rs763780) генлари полиморфизмларининг вульгар псориаз кечиши оғирлиги билан боғлиқлигини ва прогностик аҳамиятини баҳолаш ўтказилиб, 98 нафар бемор касаллик оғирлиги бўйича уч гуруҳга ажратилди: енгил (n=38), ўрта оғир (n=32) ва оғир (n=28) даража. Назорат гуруҳини 95 нафар соғлом шахс ташкил этди. Аллел ва генотип частоталари χ² ва Фишер мезонлари билан солиштирилди; тенденция Кокрен–Армитаж мезони билан баҳоланди. Олинган натижалар бўйича иккала локусда ҳам минор аллел частотаси назоратдан енгил, ўрта оғир ва оғир даражага қараб изчил ошиб борди (тенденция: IL23R — p=0,002; IL17F — p<0,001). Оғир даражада IL23R A аллели 10,7% (OR=11,28; 95% ИО 2,21–57,60; p=0,0003), IL17F G аллели 30,4% (OR=6,47; 2,86–14,63; p<0,001) ни ташкил этди, енгил ва ўрта оғир даражаларда эса фарқ ишончли бўлмади. Беморлар гуруҳи ичида солиштирганда (оғир даражага қарши енгил+ўрта оғир) фақат IL17F бўйича ишончли фарқ сақланди (OR=2,78; 1,31–5,86; p=0,006). Хулоса: IL17F C/G полиморфизми вульгар псориазнинг оғир кечиши билан боғланган ва кечишни башорат қилишда қўшимча аҳамиятга эга бўлиши мумкин; IL23R бўйича боғлиқлик асосан соғлом шахслар билан солиштирганда намоён бўлади.
##plugins.themes.default.displayStats.downloads##
Havolalar
1. Griffiths C.E.M., Armstrong A.W., Gudjonsson J.E., Barker J.N.W.N. Psoriasis. Lancet. 2021;397(10281):1301–1315.
2. Tsoi L.C., Spain S.L., Knight J., et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet. 2012;44(12):1341–1348.
3. Hawkes J.E., Chan T.C., Krueger J.G. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645–653.
4. Blauvelt A., Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379–390.
5. Reich K., Armstrong A.W., Langley R.G., et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE). Lancet. 2019;394(10201):831–839.
6. Kawaguchi M., Takahashi D., Hizawa N., et al. IL-17F sequence variant (His161Arg) is associated with protection against asthma and antagonizes wild-type IL-17F activity. J Allergy Clin Immunol. 2006;117(4):795–801. doi:10.1016/j.jaci.2005.12.1346
7. Akadam-Teker A.B., Akşan B. Association of IL-17F rs763780 polymorphism and risk of psoriasis in Turkish population: a case-control study. An Bras Dermatol. 2024;99(3):357–361. doi:10.1016/j.abd.2023.06.006
8. Ozkol H.U., Gorgisen G., Ateş C., et al. Evaluation of the relationship of IL17A and IL17F gene polymorphisms with the response to treatment in psoriatic patients using biological drugs. Postep Dermatol Alergol. 2021;38(5):780–787. doi:10.5114/ada.2020.95383
9. Prieto-Pérez R., Cabañas R., Cabaleiro T., et al. Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis. Pharmacogenomics. 2017;18(2):157–164. doi:10.2217/pgs.15.107
10. Lee Y.H., Song G.G. Associations between interleukin-23R and interleukin-12B polymorphisms and psoriasis susceptibility: a meta-analysis. Immunol Invest. 2013;42(8):726–736. doi:10.3109/08820139.2013.810241
11. Sarin R., Wu X., Abraham C. Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses. PLoS One. 2011;6(10):e25038. doi:10.1371/journal.pone.0025038
12. Yao X, Zhu Z, Manandhar U, Liao H, Yu T, Wang Y, Bian Y, Zhang B, Zhang X, Xie J, Song J. RNA-seq reveal RNA binding protein GNL3 as a key mediator in the development of psoriasis vulgaris by regulating the IL23/IL17 axis. Life Sci. 2022 Mar 15;293:119902.
13. van Vugt LJ, van den Reek JMPA, Meulewaeter E, et al. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts. J Eur Acad Dermatol Venereol. 2020;34(1):112-118.
14. Mavropoulos A., Varna A., Zafiriou E., Liaskos C., Alexiou I., Roussaki-Schulze A., Vlychou M., Katsiari C., Bogdanos D.P., Sakkas L.I. IL-10 producing Bregs are impaired in psoriatic arthritis and psoriasis and inversely correlate with IL-17- and IFNγ-producing T cells. Clin. Immunol. 2017;184:33–41.
15. Jiraskova Zakostelska Z, Reiss Z, Tlaskalova-Hogenova H, Rob F. Paradoxical Reactions to Anti-TNFα and Anti-IL-17 Treatment in Psoriasis Patients: Are Skin and/or Gut Microbiota Involved? Dermatol Ther (Heidelb). 2023 Apr;13(4):911-933.
